Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy

There is a need for the selection of those breast cancers where benefit may be attained from the addition of an anthracycline to the adjuvant chemotherapy. The expression of topoisomerase II alpha (TOP2A) protein in 3 cohorts of breast cancers treated with adjuvant dose-dense anthracycline-based che...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pathology oncology research 2012, Vol.18 (1), p.61-68
Hauptverfasser:	Nikolényi, Alíz, Uhercsák, Gabriella, Csenki, Melinda, Hamar, Sándor, Csörgő, Erika, Tánczos, Ervin, Thurzó, László, Brodowicz, Thomas, Wagnerova, Maria, Kahán, Zsuzsanna
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis of Variance Anthracyclines - administration & dosage Antigens, Neoplasm - biosynthesis Antigens, Neoplasm - metabolism Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - metabolism Cancer Research Chemotherapy, Adjuvant Disease-Free Survival DNA Topoisomerases, Type II - biosynthesis DNA Topoisomerases, Type II - metabolism DNA-Binding Proteins - biosynthesis DNA-Binding Proteins - metabolism Female Follow-Up Studies Humans Immunohistochemistry Immunology Indexing in process Kaplan-Meier Estimate Ki-67 Antigen - metabolism Middle Aged Oncology Pathology Poly-ADP-Ribose Binding Proteins Proportional Hazards Models Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There is a need for the selection of those breast cancers where benefit may be attained from the addition of an anthracycline to the adjuvant chemotherapy. The expression of topoisomerase II alpha (TOP2A) protein in 3 cohorts of breast cancers treated with adjuvant dose-dense anthracycline-based chemotherapy was determined retrospectively. The TOP2A status was analysed in relation with the other standard tumour features and the outcome. TOP2A IHC results were assessable in 106 patients: with a cut-off value of 15%, 48% of the tumours were classified as TOP2A-positive. The expression of TOP2A correlated with that of Ki67 ( R = 0.532, p
ISSN:	1219-4956 1532-2807
DOI:	10.1007/s12253-011-9417-4